Sensitivity of Mesenchymal Stem Cells and Their Progeny to Medicines Used for the Treatment of Hematoproliferative Diseases

Abstract

Cytostatic medicines affect stromal precursors in 2 ways: they decrease CFU-F concentration in the 'steady-state' bone marrow, while stimulating growth of the stromal microenvironment during its de novo formation. MSC are not sensitive to the cytostatic agents used.